Register Login

ACLARIS THERAPEUTICS, INC. (ACRS)

(99% Neutral) ACLARIS THERAPEUTICS, INC. (ACRS) Announces Enrollment Update for plans Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot April 28, 2026, 10:46 a.m.

    📋 ACLARIS THERAPEUTICS, INC. (ACRS) - Clinical Trial Update

    Filing Date: 2026-04-28

    Accepted: 2026-04-28 06:45:19

    Event Type: Clinical Trial Update

    Event Details:

    ACLARIS THERAPEUTICS, INC. (ACRS) Announces Clinical Trial Update ACLARIS THERAPEUTICS, INC. (ACRS) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: plans, potential
    • Diseases/Conditions: ATI-052 to support dosing of up to three months, ATI-052 to be best-in-class
      • Expected in 2026
      • targeting indications with heterogeneous subtypesOpportunity to Redefine the Standard in Th2 Disease • ATI-052: Harnesses the power of TSLP and IL-4R inhibition to create a potential best-in-class bispecific • Tezepelumab and Dupilumab drive multibillion dollar annual revenues across numerous indications • Combining mechanisms has the potential to better address the unmet needs across approved indications • Potential opportunities for ATI-052 • Potential first line therapy • Raise efficacy ceiling • Inhibition upstream and downstream of Th2 cascade • Faster onset, better symptom control, durable, deeper, and more consistent effect • Better address breadth of inflammatory mediators involved in Th2 diseases • Improved convenience and practical dosing schedule • Potential Q3 month dosing 4ATI-052: Potential Best-in-Class Bispecific mAb Effective Dual Binding of TSLP and IL-4Rα ATI-052 CH2 CH3 CH2 CH3 5 Same anti-TSLP antibody binding regions of Bosakitug, designed to inhibit TSLP upstream of the Th2 cascade • Retains dissociation kinetics, residence time, and potency advantages of bosakitug over comparator antibodies Designed to inhibit immune cells downstream of the Th2 cascade Anti-TSLP Fab Anti-IL4Rα scFV Fc engineered to bind more tightly to FcRn, potentially extending half-life YTE Mutation Fc mutation limits effector functionality, potentially reducing off-target binding and potential toxicity AQQ MutationDissociation of TSLP from mAbs (TR-FRET) 0 1000

    🔬 Clinical Development Pipeline (ACLARIS THERAPEUTICS, INC.):

    Product Type Development Stage Therapeutic Area Source
    ATI-2138 DRUG Phase PHASE2 Atopic Dermatitis ClinicalTrials.gov
    Energy-Based Therapy DEVICE Phase PHASE4 Rosacea ClinicalTrials.gov
    ATI-045 DRUG Phase PHASE2 Atopic Dermatitis ClinicalTrials.gov
    Placebo DRUG Phase PHASE2 Atopic Dermatitis ClinicalTrials.gov
    mFOLFIRINOX DRUG Phase PHASE1 Metastatic Pancreatic Ductal Adenocarcinoma ClinicalTrials.gov
    Zunsemetinib DRUG Phase PHASE1 Metastatic Pancreatic Ductal Adenocarcinoma ClinicalTrials.gov
    Denosumab DRUG Phase PHASE1 Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer ClinicalTrials.gov
    Zoledronic acid DRUG Phase PHASE1 Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer ClinicalTrials.gov
    Capecitabine DRUG Phase PHASE1 Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer ClinicalTrials.gov
    Zumsemetinib DRUG Phase PHASE1 Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer ClinicalTrials.gov
    ATI-2231 DRUG Phase PHASE1 Advanced Solid Tumor ClinicalTrials.gov
    Placebo Oral Tablet DRUG Phase PHASE2 Psoriatic Arthritis ClinicalTrials.gov
    ATI-450 DRUG Phase PHASE2 Psoriatic Arthritis ClinicalTrials.gov
    Vehicle DRUG Phase PHASE2 Atopic Dermatitis ClinicalTrials.gov
    ATI-1777 0.5% w/w DRUG Phase PHASE2 Atopic Dermatitis ClinicalTrials.gov
    ATI-1777 1.0% w/w DRUG Phase PHASE2 Atopic Dermatitis ClinicalTrials.gov
    ATI-1777 2.0% w/w DRUG Phase PHASE2 Atopic Dermatitis ClinicalTrials.gov
    ATI-450 20 mg oral tablet BID DRUG Phase PHASE2 Rheumatoid Arthritis ClinicalTrials.gov
    Methotrexate DRUG Phase PHASE2 Rheumatoid Arthritis ClinicalTrials.gov
    ATI-450 50 mg oral tablet BID DRUG Phase PHASE2 Rheumatoid Arthritis ClinicalTrials.gov
    BSI-045B BIOLOGICAL Phase PHASE1 Atopic Dermatitis ClinicalTrials.gov
    ATI-1777 DRUG Phase PHASE2 Atopic Dermatitis ClinicalTrials.gov
    A-101 DRUG Phase PHASE3 Common Wart ClinicalTrials.gov
    ATI 502 0.46% Topical Solution DRUG Phase PHASE2 Alopecia Areata ClinicalTrials.gov
    Active DRUG Phase PHASE3 Common Wart ClinicalTrials.gov
    ATI-501 800mg BID (High dose) DRUG Phase PHASE2 Alopecia ClinicalTrials.gov
    ATI-501 600mg BID (Mid dose) DRUG Phase PHASE2 Alopecia ClinicalTrials.gov
    ATI-501 400mg BID (Low dose) DRUG Phase PHASE2 Alopecia ClinicalTrials.gov
    ATI-502 DRUG Phase PHASE2 Atopic Dermatitis ClinicalTrials.gov
    ATI-50002 DRUG Phase PHASE2 Alopecia Areata ClinicalTrials.gov
    A-101 Topical Solution DRUG Phase PHASE4 Seborrheic Keratosis ClinicalTrials.gov
    ATI-50002 topical solution DRUG Phase PHASE2 Vitiligo ClinicalTrials.gov
    Oxymetazoline HCL 1.0% Cream DRUG Phase PHASE4 Rosacea ClinicalTrials.gov
    ATI-50002 low dose DRUG Phase PHASE2 Alopecia Areata ClinicalTrials.gov
    ATI-50002 high dose DRUG Phase PHASE2 Alopecia Areata ClinicalTrials.gov
    A-101 Vehicle Solution DRUG Phase PHASE2 Common Wart ClinicalTrials.gov
    A-101 Topical Solution 40% DRUG Phase PHASE2 Dermatosis Papulosa Nigra ClinicalTrials.gov
    Vehicle Solution DRUG Phase PHASE2 Common Warts ClinicalTrials.gov
    A-101 Solution 45 DRUG Phase PHASE2 Common Warts ClinicalTrials.gov
    A-101 Solution 40 DRUG Phase PHASE2 Common Warts ClinicalTrials.gov
    A-101 Solution DRUG Phase PHASE3 Seborrheic Keratosis ClinicalTrials.gov
    A-101 (32.5) Topical Solution DRUG Phase PHASE2 Seborrheic Keratosis ClinicalTrials.gov
    A-101 (40) Topical Solution DRUG Phase PHASE2 Seborrheic Keratosis ClinicalTrials.gov
    A-101 Vehicle DRUG Phase PHASE2 Seborrheic Keratosis ClinicalTrials.gov
    A-101 40% DRUG Phase PHASE1 Seborrheic Keratosis (SK) ClinicalTrials.gov
    A-101 32.5% DRUG Phase PHASE1 Seborrheic Keratosis (SK) ClinicalTrials.gov
    A-101 25% DRUG Phase PHASE1 Seborrheic Keratosis (SK) ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: ACLARIS THERAPEUTICS, INC.
    • Ticker Symbol: ACRS

Search

News categories